The cardiovascular effects of atracurium and it's metabolite
- Cite this article as:
- Fukushima, K., Aoki, T., Watanabe, K. et al. J Anesth (1990) 4: 45. doi:10.1007/s0054000040045
- 28 Downloads
The administration of atracurium to humans has been reported to produce little cardiovascular effects in clinical doses. The cardiovascular effect, histamine-releasing and catecholamine releasing effects of intravenous injection of atracurium 0.6 and 1.2 mg·kg−1 were studied in man, and also the cardiovascular and catecholamine releasing effects of laudanosine which is a metabolite of atracurium by Hofmann degeneration, were studied in dogs. The increase in human plasma concentration of histamine, hypotension and tachycardia were found with the dose of atracurium 1.2 mg·kg−1. The intravenous administration of laudanosine 10 μg·kg−1 to dogs produced minimal epinephrine, norepinephrine releases and cardiovascular changes.